1. Lenalidomide in solid tumors

   • Angela Segler
   • Apostolia-Maria Tsimberidou

   Review Article 15 May 2012 Pages: 1393 - 1406

   

2. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib

   • Francesco Grossi
   • Erika Rijavec
   • Paolo Pronzato

   Original Article 21 February 2012 Pages: 1407 - 1412

3. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

   • Mei Dong
   • Zhi-Qiang Ning
   • Feng-Yi Feng

   Original Article 24 February 2012 Pages: 1413 - 1422

   

4. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent

   • Elizabeth Rayburn
   • Wei Wang
   • Ruiwen Zhang

   Original Article 25 February 2012 Pages: 1423 - 1431

   

5. A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults

   • Joseph P. Boni
   • Cathie Leister
   • Daryl Sonnichsen

   Original Article 26 February 2012 Pages: 1433 - 1442

   

6. The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum

   • Fa-Jun Xie
   • Peng Zhao
   • Yi-Ping Zhang

   Original Article 28 February 2012 Pages: 1443 - 1448

   

7. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity

   • Omar N. Al Safarjalani
   • Reem Rais
   • Mahmoud H. el Kouni

   Original Article 29 February 2012 Pages: 1449 - 1455

8. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study

   • Robert S. Jansen
   • Hilde Rosing
   • Jos H. Beijnen

   Original Article 01 March 2012 Pages: 1457 - 1466

   

9. Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

   • E. Calvo
   • J. B. Vermorken
   • J. Bennouna

   Original Article 01 March 2012 Pages: 1467 - 1475

   

10. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

    • Hajime Asahina
    • Yosuke Tamura
    • Tomohide Tamura

    Original Article Open access 02 March 2012 Pages: 1477 - 1486

    

11. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

    • Qian Liu
    • Jessica D. Sun
    • Charles P. Hart

    Original Article 02 March 2012 Pages: 1487 - 1498

    

12. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer

    • Manabu Emi
    • Jun Hihara
    • Yuji Murakami

    Original Article 02 March 2012 Pages: 1499 - 1505

    

13. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

    • David A. Reardon
    • Charles A. Conrad
    • W. K. Alfred Yung

    Original Article 07 March 2012 Pages: 1507 - 1518

    

14. 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma

    • Aaron M. Teitelbaum
    • Jose L. Gallardo
    • David M. Ferguson

    Original Article 09 March 2012 Pages: 1519 - 1527

    

15. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer

    • Maiko Asakuma
    • Michiko Yamamoto
    • Noriyuki Masuda

    Original Article 14 March 2012 Pages: 1529 - 1536

16. Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients

    • Manabu Kume
    • Hiroyuki Yasui
    • Tsutomu Nakamura

    Original Article 22 March 2012 Pages: 1537 - 1544

    

17. The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells

    • Yuko Takeba
    • Naoki Matsumoto
    • Takehito Otsubo

    Original Article 06 April 2012 Pages: 1545 - 1555

    

18. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin

    • Federica Grosso
    • Maurizio D’Incalci
    • Ian Judson

    Original Article Open access 07 April 2012 Pages: 1557 - 1565

    

19. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions

    • Binfeng Xia
    • Tycho Heimbach
    • Eugene Tan

    Original Article 11 April 2012 Pages: 1567 - 1582

    

20. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men

    • M. Acharya
    • A. Bernard
    • N. Tran

    Original Article Open access 18 April 2012 Pages: 1583 - 1590

    

21. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens

    • M. J. Lamas
    • G. Duran
    • F. Barros

    Original Article 26 April 2012 Pages: 1591 - 1599

    

22. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

    • Annett Mueller
    • Erika Bachmann
    • Markus Moehler

    Original Article 29 April 2012 Pages: 1601 - 1615

    

23. An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel

    • Toshitaka Uchiyama
    • Hitoshi Kanno
    • Kayoko Saito

    Original Article 06 May 2012 Pages: 1617 - 1624

    

24. A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI)

    • Naoya Hida
    • Hiroaki Okamoto
    • Koshiro Watanabe

    Original Article Open access 08 May 2012 Pages: 1625 - 1631

    

25. RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR

    • Ziwei Liu
    • Qianying Yuan
    • Jinlan Ruan

    Original Article 08 May 2012 Pages: 1633 - 1640

    

26. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

    • Alberto Zaniboni
    • Enrico Aitini
    • Roberto Labianca

    Original Article 11 May 2012 Pages: 1641 - 1645

27. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies

    • Zhen-Hua Wang
    • Qin-Yan Gao
    • Jing-Yuan Fang

    Original Article 18 May 2012 Pages: 1647 - 1655

    

28. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl⁺ hematological malignancies

    • Prithviraj Bose
    • Edward B. Perkins
    • Steven Grant

    Clinical Trial Report 15 February 2012 Pages: 1657 - 1667

    

29. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model

    • Sarah R. Mudd
    • Martin J. Voorbach
    • Mark Day

    Short Communication 12 February 2012 Pages: 1669 - 1672

    

30. Ascorbic acid and healthy lymphocytes: a way to explain anticancer activity?

    • Sandra Rodemeister
    • Donatus Nohr
    • Hans K. Biesalski

    Letter to the Editor 14 February 2012 Pages: 1673 - 1674

31. Reply

    • S. M. Hadi

    Reply 03 April 2012 Pages: 1675 - 1675